Article Text

Download PDFPDF
D03 Quality control for plasma and cerebrospinal fluid samples using mass spectrometry
  1. Niels H Skotte1,
  2. Phillip E Geyer1,2,
  3. Martin Steger2,
  4. Peter V Treit2,
  5. Eugenia Voytik2,
  6. Marie NN Hellem3,
  7. Jørgen E Nielsen3,
  8. Matthias Mann1,2
  1. 1Faculty of Health Sciences, Department of Proteomics, The Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen, Denmark
  2. 2Department of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
  3. 3Department of Neurology, Danish Dementia Research Centre, Neurogenetics Clinic, Rigshospitalet, Denmark


Identification and quantification of disease-associated proteins in human biofluids is much needed for monitoring disease progression in HD gene expression carriers as well as providing means for monitoring therapeutic intervention. We believe studying biofluids with cutting-edge proteomics tools will help these unmet needs and provide novel leads for further validation and use in the clinic.

To this end, the cerebrospinal fluid (CSF) is an accessible source enriched for brain derived peptides as well as proteins, which allows us to investigate changes in the CNS physiology. Similarly, plasma is of great importance for evaluating systemic changes in protein secretion and can act as a secondary source of CSF proteins drained into and found in blood circulation.

High-throughput quantitative analysis of plasma and CSF is challenging because of the high dynamic range of protein abundances. However, dramatic improvements in mass spectrometry (MS)-based proteomics and advances biofluid proteome profiling have recently been achieved, which have rekindled the interest and the hope for new biomarker discoveries.

Here, we describe our robust and streamlined shotgun proteomics pipeline that allows rapid and unbiased analysis of hundreds of proteins in plasma and CSF and introduce sample quality control criteria that may provide valuable insights in understanding preanalytical variables as well as forming the foundation for sample inclusion/exclusion for future biomarker studies.

  • Biomarker
  • Plasma
  • Cerebrospinal fluid
  • Quality control
  • mass spectrometry
  • proteomics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.